Paola Celedon

Paola Celedon


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ESEmily F. Santos
Emily F. Santos
RDRamona T. Daltro
Ramona T. Daltro
CRCarlos G. Regis-Silva
Carlos G. Regis-Silva
TPTycha Bianca Sabaini Pavan
Tycha Bianca Sabaini Pavan
FOFabrícia A. de Oliveira
Fabrícia A. de Oliveira
Fred SantosFred Santos
Fred Santos
This study focuses on developing accurate immunoassays for diagnosing Chagas disease (CD), a challenging task due to antigenic similarities between Trypanosoma cruzi and other parasites, leading to cross-reactivity. To address this challenge, chimeric recombinant T. cruzi antigens (IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4) were synthesized to enhance specificity and reduce cross-reactivity in tests. While these antigens showed minimal cross-reactivity with leishmaniasis, their performance with other trypanosomatid infections was unclear. This study aimed to assess the diagnostic potential of these IBMP antigens for detecting CD in patients with Crithidia sp. LVH-60A, a parasite linked to visceral leishmaniasis-like symptoms in Brazil. This study involved seven Crithidia sp. LVH-60A patients and three Leishmania infantum patients. The results indicated that these IBMP antigens displayed 100% sensitivity, with specificity ranging from 87.5% to 100%, and accuracy values between 90% and 100%. No cross-reactivity was observed with Crithidia sp. LVH-60A, and only one L. infantum-positive sample showed limited cross-reactivity with IBMP-8.1. This study suggests that IBMP antigens offer promising diagnostic performance, with minimal cross-reactivity in regions where T. cruzi and other trypanosomatids are prevalent. However, further research with a larger number of Crithidia sp. LVH-60A-positive samples is needed to comprehensively evaluate antigen cross-reactivity.

8 January 2025 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
NFNatália Erdens Maron Freitas
Natália Erdens Maron Freitas
DCDenis Augusto Argolo Campos
Denis Augusto Argolo Campos
RFRandrin Queiroz Viana Ferreira
Randrin Queiroz Viana Ferreira
FJFelipe Silva Santos de Jesus
Felipe Silva Santos de Jesus
ÂSÂngelo Antônio Oliveira Silva
Ângelo Antônio Oliveira Silva
Fred SantosFred Santos
Fred Santos
: Chagas disease (CD), a neglected tropical disease caused by Trypanosoma cruzi, is a significant public health issue particularly in Latin America, affecting millions worldwide. Diagnosis is a challenge owing to the genetic diversity of T. cruzi and the complexities involved in selecting antigens for the detection of anti–T. cruzi antibodies. This study evaluated four chimeric recombinant antigens (IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4) designed to enhance diagnostic accuracy by addressing assay variability. We compared the diagnostic performance of these chimeric antigens using indirect ELISA as a diagnostic platform, with three commercial serological assays in Brazil, analyzing 100 serum samples from individuals with confirmed CD and 86 from non-infected controls. The results revealed that all assays and antigens demonstrated an area under the receiver operating characteristic curve of 100%, signifying their exceptional ability to distinguish between CD-positive and CD-negative samples. Notably, the chimeric antigens achieved 100% sensitivity, specificity, accuracy, and kappa index, equaling or surpassing the commercial assays. This research highlights the efficacy of IBMP chimeric antigens as reliable diagnostic tools for CD, suggesting their potential integration into commercial diagnostic platforms to enhance the accuracy and reliability of CD detection.

7 October 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
NSNeci Matos Soares
Neci Matos Soares
NBNilo Manoel Pereira Vieira Barreto
Nilo Manoel Pereira Vieira Barreto
MFMarina Morena Brito Farias
Marina Morena Brito Farias
COCíntia de Lima Oliveira
Cíntia de Lima Oliveira
WAWeslei Almeida Costa Araújo
Weslei Almeida Costa Araújo
Fred SantosFred Santos
Fred Santos
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, is a neglected tropical disease with life-threatening implications. In this study, we conducted a seroepidemiological survey to determine the prevalence and clinical profiles of CD in 217 individuals from an impoverished rural community in Southern Bahia, Brazil. The overall prevalence of CD in the studied community was 0.92%, detected through latent class analysis (LCA). Two individuals tested positive for anti-T. cruzi IgG, both being male farmers. One case was a 22-year-old man born in Camamu, with no evidence of congenital transmission, suggesting other routes of transmission such as vector-borne transmission due to migratory activities. The other case was a 69-year-old man born in São Felipe, who had lived in an adobe/brick house and had a pacemaker due to cardiac involvement caused by CD. The prevalence in this community was lower than expected, given the socioeconomic conditions and environmental factors that contribute to T. cruzi transmission. This could be attributed to the implementation of preventive measures and vector control programs by the Brazilian Government. However, continuous monitoring and surveillance are essential to sustain control efforts and detect any potential re-emergence of the disease. While the overall prevalence was low, the detection of positive cases underscores the need for continued surveillance and control measures in vulnerable populations, such as rural communities. Active surveillance, early diagnosis, and timely treatment are crucial in preventing disease progression and complications, thereby enhancing the effectiveness of screening and treatment programs.

7 December 2025 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
NFNatália Dantas Fontes
Natália Dantas Fontes
FHFernanda Lopes Habib
Fernanda Lopes Habib
Leonardo Maia LeonyLeonardo Maia Leony
Leonardo Maia Leony
NFNatalia Erdens Maron Freitas
Natalia Erdens Maron Freitas
ÂSÂngelo Antônio Oliveira Silva
Ângelo Antônio Oliveira Silva
Fred SantosFred Santos
Fred Santos
Background: Dogs are recognized as epidemiologically significant reservoirs for Trypanosoma cruzi , the causative agent of Chagas disease (CD), owing to their close association with humans and their role in sustaining the domestic and peridomestic transmission cycle. Canine seropositivity often correlates with human CD prevalence. However, the lack of commercial, high-performance diagnostic assays for canine infections remains a significant barrier to effective surveillance. Previously, our group demonstrated the diagnostic potential of four chimeric T. cruzi antigens in a phase I study, yielding results comparable to those observed in humans. The present phase II study expands upon these findings by evaluating these antigens in a larger canine cohort using indirect enzyme-linked immunosorbent assay (ELISA). The objective of this study was to assess the diagnostic performance of four chimeric recombinant T. cruzi antigens (IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4) in immunoassays for the detection of anti- T. cruzi IgG in dogs with chronic Chagas disease. Methods: Immunoassays were optimized by checkerboard titration. In this phase II study, the diagnostic performance of the IBMP antigens was evaluated using 1260 canine serum samples. Cross-reactivity was assessed in an additional 752 samples from dogs with unrelated infectious diseases. The performance of the chimeric antigens was compared with a commercial human-adapted assay (Gold ELISA Chagas). Results: The Instituto de Biologia Molecular do Paraná (IBMP) antigens demonstrated area under the curve (AUC) values ranging from 89.0% to 97.4%, with diagnostic accuracy between 87.4% and 96%. IBMP-8.2 exhibited the highest sensitivity (90.3%), while IBMP-8.1, IBMP-8.3, and IBMP-8.4 achieved sensitivities of 74.8%, 72.6%, and 79.6%, respectively. The highest specificity was observed for IBMP-8.4 (99.6%), followed by IBMP-8.3 (99.0%), IBMP-8.2 (96.5%), and IBMP-8.1 (90.6%). The Gold ELISA Chagas assay showed a sensitivity of 62.3%, specificity of 98.6%, and accuracy of 89.9%. IBMP-8.2 exhibited the lowest cross-reactivity index (0.9%), closely approximating an ideal diagnostic assay. Conclusions: The IBMP chimeric antigens demonstrated strong diagnostic performance for detecting T. cruzi infection in dogs, significantly enhancing immunoassay accuracy and minimizing diagnostic failures due to cross-reactivity. The combined use of these antigens represents a promising strategy to further improve sensitivity and specificity in future diagnostic applications. Graphical

13 July 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
SMSibelle Botogosque Mattar
Sibelle Botogosque Mattar
PCPaola Celedon
Paola Celedon
Leonardo Maia LeonyLeonardo Maia Leony
Leonardo Maia Leony
LVLarissa Vasconcelos
Larissa Vasconcelos
DSDaniel Dias Sampaio
Daniel Dias Sampaio
Fred SantosFred Santos
Fred Santos
COVID-19 laboratory diagnosis primarily relies on molecular tests, highly sensitive during early infection stages with high viral loads. As the disease progresses, sensitivity decreases, requiring antibody detection. Since the beginning of the pandemic, serological tests have been developed and made available in Brazil, but their diagnostic performance varies. This study evaluated the IBMP ELISA IgA/IgM/IgG COVID-19 kit performance in detecting SARS-CoV-2 antibodies. A total of 90 samples, including 64 from COVID-19 patients and 26 pre-pandemic donors, were assessed based on time post symptom onset (0–7, 8–14, and 15–21 days). The kit showed 61% sensitivity, 100% specificity, and 72% accuracy overall. Sensitivity varied with time, being 25%, 57%, and 96% for 0–7, 8–14, and 15–21 days, respectively. Similar variations were noted in other commercial tests. The Gold ELISA COVID-19 (IgG/IgM) had sensitivities of 31%, 71%, and 100%, while the Anti-SARS-CoV-2 NCP ELISA (IgG) and Anti-SARS-CoV-2 NCP ELISA (IgM) showed varying sensitivities. The IBMP ELISA kit displayed high diagnostic capability, especially as the disease progressed, complementing COVID-19 diagnosis. Reproducibility assessment revealed minimal systematic and analytical errors. In conclusion, the IBMP ELISA IgA/IgM/IgG COVID-19 kit is a robust tool for detecting anti-SARS-CoV-2 antibodies, increasing in efficacy over the disease course, and minimizing false negatives in RT-PCR COVID-19 diagnosis.

3 April 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
ISIsabela Machado Serrano
Isabela Machado Serrano
GRGilmar Ribeiro
Gilmar Ribeiro
RSRonnei Silva Santos
Ronnei Silva Santos
JCJaqueline Silva Cruz
Jaqueline Silva Cruz
FLFernanda Cardoso Lanza
Fernanda Cardoso Lanza
MRMITERMAYER GALVAO REIS
MITERMAYER GALVAO REIS
Chagas disease (CD) is caused by the protozoan Trypanosoma cruzi, which leads to a spectrum of clinical presentations that range from asymptomatic to severe cardiac involvement. The host immune response plays a pivotal role in disease progression. Ig isotypes may contribute to disease pathogenesis. Investigating these components can provide insights into the immunopathogenic mechanisms underlying CD. This cross-sectional study aims to establish a correlation between the Ig profile of individuals infected with T. cruzi with the clinical forms of chronic CD. Serum samples were collected from partner institutions in different states of Brazil. Individuals diagnosed with chronic CD were categorized based on the clinical form of the disease. The indirect ELISA method using the recombinant chimeric Molecular Biology Institute of Paraná membrane protein 8.4 as the antigen was used to determine the Ig profile, including total IgG, IgG1, IgG2, IgG3, and IgG4. Ninety-seven serum samples from patients classified as negative (NEG, n = 38), indeterminate (IND, n = 24), mild cardiac (MC, n = 20), and severe cardiac (SC, n = 15) forms were analyzed. IgG1 exhibited greater levels compared with the other isotypes, showing a significant difference between the MC and IND groups. IgG3 levels were greater in individuals from the MC group compared with the SC group. IgG1 and IgG3 isotypes can serve as biomarkers to evaluate the progression of CD because they exhibit variations across clinical groups. Additional longitudinal studies are necessary to explore the relationship between antibody kinetics and the development of tissue damage.